lt175 and Muscular-Diseases

The preparation of a new series of 2-aryloxy-3-phenyl-propanoic acids, resulting from the introduction of a linker into the diphenyl system of the previously reported PPARalpha/gamma dual agonist 1, allowed the identification of new ligands with improved potency on PPARalpha and unchanged activity on PPARgamma. For the most interesting stereoisomers S-2 and S-4, X-ray studies in PPARgamma and docking experiments in PPARalpha provided a molecular explanation for their different behavior as full and partial agonists of PPARalpha and PPARgamma, respectively. Due to the adverse effects provoked by hypolipidemic drugs on skeletal muscle function, we also investigated the blocking activity of S-2 and S-4 on skeletal muscle membrane chloride channel conductance and found that these ligands have a pharmacological profile more beneficial compared to fibrates currently used in therapy.

Topics: Animals; Cell Line, Tumor; Chloride Channels; Chlorides; Clofibric Acid; Crystallography, X-Ray; Drug Discovery; Electric Conductivity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligands; Male; Models, Molecular; Molecular Conformation; Muscle, Skeletal; Muscular Diseases; PPAR alpha; PPAR gamma; Propionates; Rats; Rats, Wistar; Rest; Stereoisomerism; Substrate Specificity